Tempus AI Inc. Unveils AI-Driven Platform Advancing Precision Medicine and Data-Powered Healthcare

Reuters01-12
<a href="https://laohu8.com/S/TEM">Tempus AI</a> Inc. Unveils AI-Driven Platform Advancing Precision Medicine and Data-Powered Healthcare

Tempus AI Inc. delivered a presentation highlighting its advancements in AI-enabled diagnostics and precision medicine. The company outlined the scale of its platform, which is connected to over 5,000 healthcare providers across the United States, including more than 65% of U.S. academic medical centers and over 55% of oncologists. Tempus has accumulated over 45 million patient records and more than 400 petabytes of multimodal healthcare data, enabling the development and delivery of AI-driven insights for physicians, patients, and researchers. The presentation detailed the integration of genomics, clinical, and imaging data to support applications in drug discovery, therapy selection, and clinical trial matching. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment